Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of popular augmented reality interactive entertainment games and toys in China, today announced the July 30, 2019 closing of its underwritten initial public offering (“IPO”). According to the update, the IPO consisted of 2,000,000 ordinary shares priced at $4 each, before underwriting discounts … Continue reading “NetworkNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces IPO Closing”
Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of popular augmented reality interactive entertainment games and toys in China, today announced the pricing of its underwritten initial public offering (“IPO”) of 2,000,000 ordinary shares at a public offering price of $4 per share, before underwriting discounts and commissions. .According to the … Continue reading “NetworkNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces IPO Pricing and Increases Offering Size”
China’s AR industry is estimated at RMB$55 billion in 2020 Favorable Chinese government policies emphasize research and development of new technologies such as AR Few direct competitors in China create exceptional potential for AR application in educational materials and smart toys Total retail sales of toys and games in China soared to RMB$276.5 billion in … Continue reading “Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) is “One to Watch””
Investment Considerations China’s AR industry is estimated at RMB$55 billion in 2020 Favorable Chinese government policies emphasize research and development of new technologies such as AR Few direct competitors in China create exceptional potential for AR application in educational materials and smart toys Total retail sales of toys and games in China soared to RMB$276.5 … Continue reading “Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)”
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast … Continue reading “Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’”
Investment Considerations Lantern Pharma’s AI-driven RADR® platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline. The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL. Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications … Continue reading “Lantern Pharma Inc. (NASDAQ: LTRN)”
Soligenix (SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that its lead investigators will present findings from recent trials on HyBryte™ for cutaneous T-cell lymphoma (CTCL) and SGX302 for mild-to-moderate psoriasis at the U.S. Cutaneous Lymphoma Consortium (USCLC) Workshop on March 6, 2025, and the American Academy of Dermatology (AAD) Annual Meeting from … Continue reading “NetworkNewsBreaks – Soligenix Inc. (SNGX) to Present HyBryte™ and SGX302 Data at Dermatology Conferences “
SOHM (OTC: SHMN) is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” (Global Prosperity). SOHM was founded in 1998 and is headquartered in Chino Hills, California. The company’s primary goal is to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier … Continue reading “SOHM Inc. (SHMN) Is ‘One to Watch’”
SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, is bolstering its executive team as it eyes the globalaa nutraceuticals market, which is expected to post a CAGR of 9.4% between 2023 and 2030, and the global NSAID market which is also expected to be valued at $30 billion by 2030. SOHM’s strategic approach … Continue reading “SOHM, Inc. (SHMN) Bolsters Executive Team; Confident About Anticipated Developments and Opportunities”
SOHM (OTC: SHMN) is a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories. “SOHM is strengthening its governing team with the addition of two experienced visionaries committed to helping the company’s growth in the pharmaceutical, nutraceutical and cosmeceutical marketplace… The new officers are expected to help direct SOHM’s … Continue reading “NetworkNewsBreaks – SOHM Inc. (SHMN) Expands Team to Direct Global Growth Strategy”